Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF -7-
June 11, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 11, 2001
- Sysmex: Sales Down in US, Japan, but Up in Europe, Asia
June 11, 2001
- 2% Price Adjustment Range Needs Urgent Review: FJPWA
June 11, 2001
- Olympus: Good Sales of Medical Endoscopes Overseas Drive Sales, Profits
June 11, 2001
- Nippon BD Ties Up with TAUNS Regarding Infectious Disease Diagnosis Kits
June 11, 2001
- Richfield to Embark on MR Dispatching Business
June 11, 2001
- Olympus: New Endoscope Position Detective Unit
June 11, 2001
- Matsumotokiyoshi: Sales Up 1% but Operating Profits Down 0.9%
June 11, 2001
- Tokyo Women's Medical Univ. Introduces "MR-kun"
June 11, 2001
- Genzyme Aims at Leading Biosurgery Market
June 11, 2001
- New Quasi-drug Sales Up 8.5%, to \155.3 Bil.
June 11, 2001
- JKMA Proposes New Development for Kampo Medicines
June 11, 2001
- Boston Scientific Japan: Exxcel Soft, Artificial Blood Vessel
June 11, 2001
- WORLD NEWS IN BRIEF
June 11, 2001
- Mevalotin Inhibits Coronary Events, Cerebral Infarctions
June 11, 2001
- Sankyo to Cut Over \90 Bil. in Costs to Achieve Sales of \1,000 Bil. in FY2010: President Takato
June 11, 2001
- JPPA Kicks Off Division of Women
June 11, 2001
- 30 Major Domestic Drug Companies: Sales Up 2.1%, Profits Up 3.0%
June 11, 2001
- EAD Director Calls For Fair Trade Practices for Ethical Drugs
June 11, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…